FC
TEVA icon

Fore Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Fore Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-50,000
Closed -$2.93M – 74
2018
Q4 		$2.93M Buy
+50,000
New +$1.03M 1.44% 19

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fore Capital's TEVA Position: Q1 2018 in Review

Fore Capital sold out of Teva Pharmaceuticals (TEVA) in Q1 2018, closing a stake of 20,000 shares — an estimated $379K sold.

Fore Capital first reported a position in TEVA in Q4 2017 and held it in 1 quarter. The position peaked at $379K in Q4 2017. 507 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

  • Fore Capital reported no remaining Teva Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Fore Capital sold 20,000 Teva Pharmaceuticals shares in Q1 2018, an estimated $379K.
  • Fore Capital first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Fore Capital's Teva Pharmaceuticals position peaked at $379K in Q4 2017.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2018.

Based on Fore Capital's 13F filing for Q1 2018, filed 15 May 2018.